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Summary
Two unusual characteristics ofthe memory response to the immunodominant Epstein-Barr vi-
rus (EBV) epitope FLRGRAYGL, which associates with HLA B8, have provided an unique
opportunity to investigate selftolerance and T cell receptor (TCR) plasticity in humans. First,
the response is exceptionally restricted, dominated by cytotoxic T lymphocytes (CTL) with
identical TCR protein sequences (Argaet, V. P., C. W. Schmidt, S. R. Burrows, S. L. Silins,
M. G. Kurilla, D . L. Doolan, A. Suhrbier, D . J. Moss, E. Kieff, T. B. Sculley, and I. S. Misko.
1994. J. Exp. Med. 180:2335-2340). Second, CTL expressing this receptor are cross-reactive
with the alloantigen HLA B*4402 on uninfected cells (Burrows, S. R., R. Khanna, J . M. Bur-
rows, and D . J. Moss. 1994. J. Exp. Med. 179:1155-1161) . No CTL using this conserved pub-
lic TCR could be reactivated from the peripheral blood of EBV exposed individuals expressing
both HLA B8 and B*4402, demonstrating the clonal inactivation of potentially self-reactive T
cells in humans. A significant FLRGRAYGL-specific response was still apparent, however, and
TCR sequence analysis of multiple CTL clones revealed an oligoclonal TCR repertoire for
this determinant within these individuals, using diverse V and J gene segments and CDR3 re-
gions. In addition, a significant public TCR component was identified in which several distinct
cx/R rearrangements are shared by CTL clones from a number of unrelated HLA B8+ ,
B*4402 + donors. The striking dominance ofpublic TCR in the response to this EBV epitope
suggests a strong genetic bias in TCR gene recombination. Fine specificity analysis using pep-
tide analogues showed that, of six different antigen receptors for FLRGRAYGL/HLA B8,
none associate closely with the peptide's full array of potential TCR contact residues. Whereas
the HLA B*4402-cross-reactive receptor binds amino acids toward the COOH terminus of
the peptide, others preferentially favor an NHZ-terminal determinant, presumably evading an
area that mimics a structure presented on HLA B*4402. Thus, tolerance to a background major
histocompatibility antigen can effectively diversify the TCR repertoire for a foreign epitope by
deflecting the response away from an immunodominant combination ofTCR-binding residues.
T
cells that express the aR TCR heterodimer recognize
immunogenic peptides presented by self-MHC mole-
cules. TCR diversity arises during T cell development in
the thymus by rearrangement of variable (TCRAV and
TCRBV), diversity (TCRBD), and joining (TCRAJ and
TCRBJ) gene segments, as well as N region diversity at the
junctional regions (1, 2). The hypervariable complementar-
ity determining region 3 (CDR3)' spans the junctional re-
gions and interacts directly with peptide epitopes (3) . The
'Abbreviations used in this paper: CDR3, complementarity determining re-
gion 3; CTLp, CTLprecursor; LCL, lymphoblastoid cell line; LDA, lim-
iting dilution analysis.
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mature T cell repertoire expresses only a small proportion
of potential T cell specificities resulting from selective pro-
cesses which include the inactivation of self-reactive T cell
clones. This tolerance to self-antigens has been studied mainly
in rodents, where clonal deletion during early ontogeny
plays a major role. In addition, tolerance is established in
the thymus and the periphery by a second mechanism that
results in clonal anergy (4, 5). The repertoire of TCR is
also powerfully biased by positive selection for self-MHC
restriction which, like clonal deletion, involves recognition
ofself-peptide/MHC complexes in the thymus (6, 7) . Sim-
ilar mechanisms presumably account for the influence of
HLA on TCR V segment frequencies and expression levels
in peripheral blood (8) .
An important effect of self-tolerance is that it can poten-
1703
￿
J. Exp. Med. © The Rockefeller University Press " 0022-1007/95/12/1703/13 $2.00
Volume 182 December 1995 1703-1715tially create holes in the repertoire of TCR for foreign an-
tigens with self homology. This has been demonstrated in
mice indirectly by the inability of certain MHC-bound
peptides to induce an immune response (9, 10), and more
directly where molecular mimicry was shown to be the ba-
sis for unresponsiveness to the syntheticpolymer, poly (Glus°-
Tyrs°) (11) . In contrast, other evidence has suggested that
the murine TCR repertoire has sufficient plasticity to re-
spond to a broad range of antigenic peptides capable of
binding to the MHC (12) . TCR plasticity has also been in-
vestigated using mouse strains with a deficiency of T cells
bearing particular TCRBV genes. This may result from ei-
ther deletion mutations ofTCR genes or from tolerance to
endogenous superantigens, a group of molecules that bind
specific (3 chains of the TCR essentially independent of ei-
ther the cx chain or the peptide occupying the pocket (13).
T cell responses to peptides that normally show restricted
TCRBV usage are either crippled (14, 15) or modified
(16-18) in mice lacking the relevant (3 chain. Similar stud-
ies have notbeen possible in humans primarily because en-
dogenous superantigens and TCRBV-specific T cell dele-
tions have not yet been documented in this species. In any
case, these results may not reflect the more specific con-
straints imposed on a TCR repertoire by tolerance to a
conventional self-antigen that interacts with both TCR ot
and R chains.
The inununodominant EBV epitope FLRGRAYGL
(19), in association with HLA 138, induces an exceptionally
restricted memory response that is dominated by CTL with
an invariant public TCR (20, 21) that is cross-reactive with
the alloantigen HLA B*4402 (22). Herein, we describe the
clonal inactivation of these potentially self-reactive T cells
in EBV-sero+ people who are both HLA138' and13*4402'.
The human TCR repertoire is sufficiently flexible to com-
pensate for this loss, however, and these individuals re-
spond to the peptide with an oligoclonal repertoire that in-
cludes a significant public component (i.e., homologous
TCR shared by more than one individual). Recognition
by these clones of single amino acid-substituted analogues
of peptide FLRGRAYGL revealed that tolerance to HLA
B*4402 obstructs the normally immunodominant response
to a distinct determinant within the nonamerpeptide which,
in its MHC-associated form, mimics a structure on HLA
B*4402 .
Materials and Methods
Establishment andMaintenance ofCell Lines.
￿
Short-term CTL mi-
crocultures were generated by limiting dilution as follows: PBMC
were distributed in round-bottomed microciter plates in growth
medium (10% FCS/RPMI 1640) at cell numbers per well below
the anti-FLRGRAYGL CTLp frequency estimates for each do-
nor (see Fig. 3), e.g., 103 cells per well for HLA B*4402- indi-
viduals and 3 X 103 cells per well for HLA B*4402+ individuals.
Approximately 5 X 104 -y-irradiated (2,000 rads) autologous
PBMC, which had been preincubated with peptide FLRGRA-
YGL (1 Ir,M for 1 h), were added to each well to give a total vol-
ume of 100 RI. Cultures were fed on days 4 and 7 with 50 ILl of
medium supplemented with 20 U of rIL-2 (23, 24) and 25%
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(vol/vol) supernatant from MLA-144 cultures (TIB-201 ; Ameri-
can Type Culture Collection, Rockville, MD). On day 10, each
CTL microculture was split into three replicates whichwere used
as effectors in a standard 5-h "Crrelease assay.
CTL clones were generated by agar cloning as follows: 2 X 106
PBMC were stimulated in 2 ml ofgrowth medium with autolo-
gous cells presenting the epitope FLRGRAYGL. These stimula-
tors were either PBMC pretoatedwith thepeptide FLRGRAYGL
(1 Ir,M for 1 h) or the -y-irradiated (8,000 rads) lymphoblastoid
cell line (LCL) (responder/stimulator ratio = 5:1 or 50 :1, respec-
tively). After 3 d, cells were dispersed and seeded in 0.35% aga-
rose (Seaplaque; FMC BioProducts, Rockland, ME) containing
55% RPMI 1640, 20% FCS, 25% supernatant from MLA-144
cultures, and 30 U/ml rIL-2. Colonies were harvested after an ad-
ditional 3-4 d and were amplified in culture with biweekly restim-
ulation with rIL-2, MLA-144 supernatant, and the -y-irradiated
(8,000 rads) autologous LCL. CTL clone LC13 has been de-
scribed previously (20, 25).
PHA blasts were generated by stimulating PBMC with PHA
(CSL, Melbourne, Australia), and after 3 d, growth medium con-
taining MLA-144 supernatant and rIL-2 was added. PHA blasts
were propagated with biweekly replacement of rIL-2 and MLA-
144 supernatant (PHA-free) for up to 8 wk. LCLwere established
by exogenous transformation ofperipheral B cells (26) with EBV
derived from the IARC-BL74 cell line, which encodes the epitope
FLRGRAYGL (27) . All cell lines were regularly screened for my-
coplasma contamination. Blood donors used in this study were
healthy laboratory staffmembers selected forparticular HLA alleles.
Cytotoxicity Assay.
￿
CTL clones were tested in duplicate for
cytotoxicity in the standard 5-h chromium release assay (E/T ra-
tio of 1:1). Briefly, CTL were assayed against s'Cr-labeled PHA-
blast targets that were pretreated with the peptide FLRGRAYGL
(1 IiM for 1 h) and were either washed or left untreated. In avari-
ation of this method, used when screening the large number of
FLRGRAYGL analogues, peptides were added directly to ''Cr-
labeled targets and remained present throughout the assay. A beta
scintillation counter (Topcount Microplate; Packard Instrument
Co., Meriden, CT) was used to measure 5'Crlevels in assay super-
natant samples. The mean spontaneous lysis for target cells in cul-
ture medium was <20%, andthe variation about the mean specific
lysis was <5%. Peptides were synthesized by Chiron Mimotopes
(Chiron Corp., Emeryville, CA) usingpin technology (28). Rec-
ognition by the CTL clone LC13 of monosubstituted analogues
ofthe peptide FLRGRAYGL, which had a (3-alanine-diketopiper-
azine group at the COOH-termini, has been reported previously
(19) . Since these peptides were found to be much less active than
corresponding peptides synthesized with free acid COOH ter-
mini (data not shown), all peptides used in this study were made
with unblocked COON and NH= termini. Toxicity testing of all
peptides was performed before screening by adding each peptide
to PHA blasts in the absence of CTL effectors.
Amplification and Sequencing of Rearranged TCRA and TCRB.
Fresh or frozen samples of CTL clones were obtained for analysis.
Cells were washed three times in PBS before freezing and/or
processing. Poly A+ RNA was extracted from 1-5 X 106 CTL
using an mRNA purification kit (QuickPrep Micro; Phannacia
P-L Biochemicals Inc., Milwaukee, WI). Antisense TCRAC and
TCRBC primers were used to generate first-strand cDNA from
500 ng poly A+ RNA, and an anchor oligonucleotide, amino-
blocked at the3' end, was ligated to the cDNA synthesis products.
Nested TCRAC and TCRBC primers, as well as a primer com-
plementary to the anchor, were then used to amplify specific
TCRA- and TCRB-rearranged sequences (20).Nucleotide sequence analysis of recovered DNA fragments
was performed using a PRISM Ready Reaction DyeDeoxy Ter-
minator Cycle Sequencing Kit and a 373A DNA sequencer (Ap-
plied Biosystems, Inc., Foster City, CA) according to the proto-
cols described by the manufacturer. Each sequence presented in
this studywas obtained from two separate PCRs. In the eventthat
nucleotide sequence analysis ofaPCR product revealed more than
one specific sequence, the product was subsequently ligated into
the pGEM-T Vector System (Promega Corp., Madison, WI).
The nucleotide sequence of at least six clones was determined for
each ligation.
Forsome T cell clones, V(3 family-specific PCRwas performed
according to the method described by Panzara et al . (29) using
0.5 N.l anchor-ligated cDNA (diluted 1/100) and 10 pmol of each
a 5' sense primer, specific for each of the 20 known V(3 families,
and a 3' antisense primer specific for the C(3 region. Amplifica-
tions were performed in 25-N,1 reaction volumes consisting of 200
pLM dNTPs, 20 mM MgCl2, and 1.25 U o£ Taq polymerase
(Ampli-Taq) using a GeneAmp PCR 9600 system (all from Per-
kin-Elmer Cetus Corp., Norwalk, CT). ThePCR conditions con-
sisted of denaturation at 95°C for 15 s, annealing at 55°C for 40 s,
and extensionat 72°C for 40 s for 35 cycles, followed by a 5-min
final extensionat 72°C. P-actin cDNA was also amplifiedas a con-
trol for cDNA integrity (30). PCR products were excised from
2.5% (1/z X Tris-buffered EDTA) NuSieve GTG agarose gels
(FMC BioProducts) and purified using a QIAEX gel extraction
kit (Qiagen Inc., Chatsworth, CA).
Semiquantitative PCR Analysis of FLRGRAYGL-specific TCR-F3
Gene Expression inBulk T Cell Cultures. PBMC from the EBV-
sero+ donors RL, TF, CF, LC, IM, and EBV-sero- donor PGP
(HLA Al,A24,B8,B14,DR1,3) were stimulated with autologous
PBMC precoated with peptide FLRGRAYGL (1 N.M for 1 h) (re-
sponder/stimulator ratio = 5:1). After7 d, total RNAwasextracted
from 5 X 106 cells using a total RNA isolation kit (RNagents;
Promega), and first-strand cDNA was synthesized using 5 N,g of
total RNA and 10 pmol o£ an antisense TCRBC gene-specific
primer (Cb, ; 5'-TATCTGGAGTCATTGAGGGCGGGCA-3')
according to the above mentioned procedure. 200 rig of first-
strand cDNA was used as a template forPCR amplification using
a 32p-labeled TCRBV6 family-specific primer (5'-GGCCTG-
AGGGATCCGTCTC-3') and a degenerate primer complemen-
tary to the CDR3 region of the conserved (3 chain (RCDR3; 5'-
GTACTGCTC(G,A)TA(A,G,C,T)GC-3'). (3-actin cDNA was
amplified in parallel (30) for use as a standard in the calculation of
the relative abundance of the product obtained with the TCR-
BV6-(3CDR3 primer set. The amplification schedule was 94°C for
20 s, 60°C for 20 s, and 72°C for 20 s. Amplifications were per-
formed in 25-[,t reaction volumes, and samples were removed af-
ter35 cycles. The amplified products were resolved on a 6% acryl-
amide gel and exposed to a storage phosphor screen (Molecular
Dynamics, Inc., Sunnyvale, CA). Relative quantification ofthe am-
plicons was performed using a phosphorimager and ImageQuant
software version 3.3 (Molecular Dynamics). Sizes of bands were
estimated by comparison of theirmobilities relative to the migra-
tion ofa 32p-labeled 1-kb DNA ladder (GIBCO BRL, Gaithers-
burg, MD).
Limitinq Dilution Analysis (LDA).
￿
PBMC were distributed in
graded numbers from 103to 104 cells perwell in round-bottomed
microtiter plates . Approximately 5 X 10^ -y-irradiated (2,000 rads)
autologous PBMC, which had been preincubated with FLR-
GRAYGL (1 p,M for 1 h), were addedto each well to give a total
volume of 100 p,l. Cultures were fed on days 4 and 7 with 50 N,l
of medium supplemented with 20 U rIL-2 and 25% supernatant
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from MLA-144 cultures. On day 10, each CTL microculture was
splitinto two replicates which were used as effectors in a standard
5-h "Cr release assay against HLA B8+ PHA blasts (SC PHA
blasts: HLA A1,A31,B8,B51,DR3,DR4) precoated with peptide
FLRGRAYGL (1 u,M for 1 h) or left uncoated (control). 36 rep-
licates were used at each concentration in each experiment. Wells
were scored as positive when the percent specific chromium re-
lease exceeded the mean release from control wells by 3 SDs.
LDA was performed by the method of maximum likelihood esti-
mation (31) . Data from all experiments were compatible with the
hypothesis of single-hit kinetics (P >0.4), and precursorestimates
are given with 95% confidence limits.
Results
Clonal Inactivation of Potentially Self-reactive T Cells in Hu-
mans. Multiple CTL microcultures were raised by limit-
ing dilution from six HLAB8+, EBV-sero+ individuals after
in vitro stimulation with the EBV epitope FLRGRAYGL.
Three of these donors (CF, RL, and TF) also express HLA
B*4402, the antigen that mimics the viral epitope in the
context of HLA 138, while the other three donors (LC, IM,
and SC) do not. Each microculture was assayed separately
for CTL activity against HLA B8+ PHA blast target cells
(SC PHA blasts: HLA Al,A31,B8,B51,DR3,DR4) with
andwithoutpeptide FLRGRAYGL, as well as HLA B*4402+
PHAblasts (SJ PHAblasts: HLA A2,A3,B7,B*4402,DRl,-).
All CTL microcultures from donors LC, IM, and SC that
recognized the EBV peptide cross-reacted with the alloan-
tigen HLA B*4402 (Fig. 1 A) . These results support earlier
evidence that the memory response to FLRGRAYGL is of-
tenremarkably restricted (20), and suggested that individuals
who are both HLA B8+ and B*4402+ may not respond to
the epitope because ofself-tolerance. As shown in Fig. 1 B,
however, donors CF, RL, and TF did respond to the epitope,
but with a repertoire ofCTL that didnot lyse HLAB*4402+
target cells significantly. This suggests that the T cell clono-
type that usually dominates the memory response for FLR-
GRAYGL is inactivated by mechanisms of self tolerance in
HLA B*4402+ individuals.
To investigate this apparent Conal inactivation more di-
rectly, PCR was used to search for the conserved, B*4402
cross-reactive TCR in bulk T cell cultures from EBV-
sero+, HLA B8+ individuals who were either positive or
negative for B*4402, after stimulation with the peptide
FLRGRAYGL. A similarly generated bulk T cell popula-
tion from an EBV-sero- donor was included as a negative
control. All T cell cultures from EBV-exposed individuals
were strongly reactive to HLA B8+ PHA blasts preincu-
bated with peptide FLRGRAYGL (data not shown). To
monitor for the conserved (3 chain of the cross-reactive re-
ceptor in the stimulated cultures, we used semiquantitative
PCR using a TCRBV6 family primer (TCRBV6) and a
degenerate primer complementary to the TCRB CDR3 re-
gion of the conserved receptor for FLRGRAYGL (RCDR3)
(20) . Comparison of the normalized PCR, profiles using a
phosphorimager revealed that a DNA band with the ex-
pected mobility of an amplified product encoding the con-50
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Cross-reactivity with alloamigen HLA B*4402 by CTL mi-
crocultures raised against FLRGRAYGL/HLA B8 . Multiple CTL mi-
crocultures from three HLA B8+ , B*4402- (Fig. 1 A) and three HLA
B8+ , B*4402+ (Fig . 1 B) individuals were tested for lysis ofSJ PHA blasts
(HLA B*4402+ ; vertical axis), and SC PHA blasts preincubated with pep-
tide FLRGRAYGL (HLA B8+ ; horizontal axis) . SC PHA blasts were also
used as targets without peptide presensitization (data not shown) ; these were
lysed by <5% of CTL microcultures, and data from these are not included.
Data from CTL microcultures that failed to significantly lyse any targets
are also excluded. HLA types of the six donors are as follows : LC, HLA
Al, -,B8,Bl8,DR3,DRll ; IM, HLA Al,A11,B8,B51,DR3,DR7;SC,
HLA A1,A3l,B8,B51,DR3,DR4 ; CF, HLA A1,A2,B8,B*4402,DR3,
DR4 ; RL, HLA Al,A2,B8,B*4402 ; and TF, HLA Al,A2,B8,B*4402,
DR3,DR4 .
served TCR (3 chain could be detected in T cell popula-
tions from HLA B*4402- , EBV-sero+ donors, but not from
either the EBV-sero- donor or HLA B*4402+ , EBV-sero+
donors (Fig . 2) . Direct sequencing of the PCR products
showed that only one nucleotide sequence was amplified
from donors LC and IM, and these were identical to those
found in CTL clones raised previously from these donors
(20) . These data, together with the functional assays, dem-
onstrate the clonal inactivation of potentially self-reactive T
cells in humans .
To quantitate the influence ofHLA B*4402 expression
on the memory response to FLRGRAYGL, we compared
estimates ofCTL precursor (CTLp) frequencies for this pep-
tide between the six EBV-sero + individuals examined above
T Cell Repertoire Diversified by Self-tolerance
Figure 2 .
￿
Detection of the conserved 13 chain of the TCR with dual
reactivity for FLRGRAYGL/HLA B8 and B*4402 . Semiquantitative
RT-PCR analysis for the conserved 13 chain of the TCR with dual reac-
tivity for FLRGRAYGL/HLA B8 and B*4402 in bulk FLRGRAYGL-
stimulated T cell cultures from six individuals. These were donors LC,
IM (EBV-sero+, HLA B8+ , B*4402- ), CF, RL, TF (EBV-sero`, HLA
B8+ , B*4402+), and PGP (EBV-sero - , HLA B8+ , B*4402- ) . 13-actin
cDNA was coamplified (30) for use as a standard in the calculation ofthe
relative abundance of the product obtained with the TCRBV6-PCDR3
primer set (data not shown) . The relative mobilities ofthese amplicons are
indicated by arrows.
using LDA . As shown in Fig . 3, CTLp frequencies for three
HLA B*4402+ donors (1 per 6,290, 7,620, and 7,560 PBMC)
were less than those estimated for three B*4402- donors (1
per 1,940, 1,880, and 2,760 PBMC) . No CTLp for the pep-
tide were detected in PBMC from three EBV-sero- , HLA
B8+ donors (one ofwhom was also B*4402+ ), included as
negative controls (data not shown) . Thus inactivation of
the usually dominant clonotype appears to restrain, but not
prevent, this T cell response to a viral epitope .
TCR Repertoire for a Viral Epitope is Diversified by Setf-
MHC Tolerance . We have previously shown that identical
TCR protein sequences are used by clones for peptide FLR-
GRAYGL from each of four HLA B*4402- unrelated vi-
rus carriers (20) . To investigate the TCR repertoire used
for this epitope in the absence of this "prototypical" recep-
tor, 10 CD8+ CTL clones that recognize FLRGRAYGL
were raised from donor CF (HLA Al,A2,B8,B*4402 ,
DR3,DR4) using agar cloning . None were found to be
cross-reactive with HLA B*4402 (data not shown) . TCRA-
(VJ-C) and TCRB(V-DJ-C) rearrangements expressed
by these clones were identified using a modification of the
single-strand ligation to single-stranded cDNA technique
(SLIC) (32, 33), as previously described (20), followed by
direct sequencing ofSLIC-generated PCR products. Align-Figure 3 .
￿
CTLp frequencies forEBV epitope FLRGRAYGL in HLA
B*4402- versus B*4402+ individuals . Using limiting dilution analysis, the
frequencies ofCTLp for peptide FLRGRAYGL were estimated inPBMC
from six donors . These were HLA B8+ , B*4402- donors LC, IM, and
SC (light shading in A, B, and C, respectively) and HLA B8+, B*4402+
donors CF, RL, and TF (dark shading in A, B, and C, respectively) . Re-
ciprocal values of responder frequencies Y- ') are indicated. The shaded
areas indicate 95% confidence limits .
ment offunctional TCRA and TCRB nucleotide and poly-
peptide sequences (Fig . 4) revealed that each clone expresses
one of five distinct TCR-ap heterodimers . Also shown in
Fig . 4, for comparison, are the TCR functional regions of
the CTL clone LC13 (20, 25), isolated from a B*4402- in-
dividual, with dual reactivity to FLRGRAYGL/HLA B8
and the alloantigen HLA B*4402 .
Sequence comparison of the different TCR for FLR-
GRAYGL/HLA B8 revealed little apparent homology within
the CDR3 regions and, with the exception ofclones CF6/
34/40 and CF9, no conservation ofTCRV or TCRJ seg-
ments . Clones CF6/34/40 and CF9, however, express very
similar TCRV and TCRAJ genetic elements (TCRDV-
104S2J17S3 and TCRBV21S4), and they differ only in
TCRBJ usage and CDR3 sequence in both chains . Apart
from a few conserved amino acids shared between the non-
germline encoded regions of the CDR3 loops in both chains
of these TCR, there is no apparent conservation ofCDR3
amino acid composition . Interestingly, the clones from do-
nor CF were raised from three different bleeds during a 12-
month period (bleed 1, CF3 ; bleed 2, CF4, 6, 9, 24, 36,
and 42 ; bleed 3, CF8, 34 and 40) . The isolation ofT cells
using identical TCR from bleeds several months apart indi-
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cates antigen-driven clonal expansion in this memory CTL
response .
To further investigate the TCR repertoire for FLR-
GRAYGL/HLA B8 in the absence of the prototypical re-
ceptor, CTL clones were established from another four
HLAB8+ , B*4402+ , EBV-sero+ unrelated individuals (R-L,
TF, MH, and PP) . As with donor CF, these individuals use
a number o£ different TCR-a/(3 combinations in their re-
sponse to the immunodominant FLRGRAYGL petpide
(Fig . 5) . 3 out of 10 CTL clones (RL10/45 and RL16) were
shown to have two in-phase a chain rearrangements . The
clonality of these T cell lines was confirmed by VP family-
specific PCR and nucleotide sequencing, which detected a
single in-frame (3 chain (data not shown) . In addition, non-
productively rearranged a and (3 chain transcripts were de-
tected for clones PP31 and RL10/45, respectively (data not
shown) .
Comparison of the TCR sequences from all HLA B8+ ,
B*4402+ donors revealed a surprising number of highly
conserved TCR uses by different individuals (Figs . 4 and
5) . At least one clone from each of the five donors was
shown to express a TCR-R chain or -a/(3 heterodimer with
strong homology to a TCR used by at least one other do-
nor. The most striking examples are clones RL16, TF1,
and PP7, isolated from three different people, which ex-
press identical TCR except for a single conserved amino
acid substitution in the (3 chain CDR3 region of clone
RL16 . In another example, the TCR of clones CF8 and
RL10/45 share identical R protein chains and express a
chains encoded by the same TCRAV gene (TCRAV7S4),
each of which has recombined with different members of
the TCRAJ17 gene family . The CDR3 regions of these a
chains are both nine residues in length, and six ofthese res-
idues are identical at the same positions .
In a third example ofTCR conservation, clones CF6/34/
40, PP22, and PP31 all express receptors encoded by TCR-
BV21S4 rearranged to TCRBJ2S3 . The R chain CDR3 re-
gion of the CF clones differs from that of the PP clones by
a single conserved amino acid substitution . With respect to
a chain rearrangements, clones CF6/34/40 and PP22 use
different TCRV gene segments . The respective CDR3 re-
gions, however, are similar because ofrearrangement, with-
out N region additions, of the different TCRV gene seg-
ments with a common TCRAJ segment (TCRAJ17S3) . In
contrast, the productively rearranged a chain ofclone PP31
bears no homology to the a chains of either CF6/34/40 or
PP22 . Finally, R chain homology is also observed between
clones CF9 and MH12 . Both clones use TCRBV21S4 and
TCRBJ2S2, and theirCDR3 regions are identical in length,
sharing 8 out of 12 residues at corresponding positions . The
a chains of each of these clones, however, show no TCR
V, J, or CDR3 homology.
Overall, these data illustrate the dramatic influence ofHLA
B*4402 coexpression on the CTL response to this HLA
B8-restricted EBV epitope . In contrast to B*4402- individ-
uals, who have been shown to use an essentially mono-
clonal repertoire, individuals that express B*4402 mount an
oligoclonal response, and use diverse V andJ gene segmentsN W S G N T P L
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￿
tgt get agt
￿
ggt ccc eet etc caa aaa aac tat aac tac
￿
ace ttc ggt
CF24 BV18S1 C A S S P R V S G G V Y £ Q
￿
Y F G BJ2S7 BC2
CF36
￿
tgt gcc age
￿
tea cca egg gtg age gg ggg gt e tac aaa c
￿
tac tte ggg
CF42
CF8` BV7S5 C A S S H G T S G I L E T Q
￿
Y F G BJ2S5 BC2
tgc gcc age
￿
age cat aaa act aac aaa att ttg aaa ace can
￿
tac ttc ggg
CF6 " BV21S4 C A S S F T W T S G G A T D T Q Y F G BJ2S3 BC2
CF34'
￿
tgt gcc age
￿
agc tee ace tag act ace o a aaa gcc aca cat aca caa
￿
tat ttt ggc
CF40'
CF9' BV21S4 C A S S L F P T G S T A G E L
￿
F F G BJ2S2 BC2
tgt gee age
￿
age tta ttc cca aca aag agt acg gcc aga aaa cta
￿
ttt ttt gga
LC13' BV653a C A S S L G Q A Y E Q
￿
Y F G BJ2S7 BC2
tgt gcc age
￿
age tta ggg caa ace tac aaa caa
￿
tac ttc ggg
Figure 4.
￿
V-(D)Jjunctional region sequences of a and l3 chains from CTL clones that recognize FLRGRAYGL/HLA BS from the B*4402+ donor,
CF, and the B*4402- donor, LC. TCRA (A) and TCRB (B) junctional region sequences of 10 CTL clones that recognize FLRGRAYGL/HLA B8 iso-
lated from an HLA B8+, B*4402+ donor, CF. The nucleotide sequences are presented, and the one-letter code designating the translated amino acid is
shown above the first nucleotide in each codon. CTL clones are listed on the vertical axis and those expressing identical TCR sequences are grouped to-
gether. For comparison, the TCRjunctional regions ofa CTL clone from HLA B*4402- donor LC (LC13), which express the prototypical receptor for
FLRGRAYGL, are also shown. TCRV gene segments are classified according to family designations outlined by Clark et al. (34) . TCRAJ genetic ele-
ments are assigned according to the nomenclature described by Moss et al. (35). Designations for TCRBJ and TCRBC elements follow that ofToyonaga
et al. (36). For each clone, the deduced amino acid sequence ofthe CDR3-equivalent loop, defined according to Chothia et al. (37), is shown putatively
supported by two framework branches (FM . The TCRV and TCRJ segments are consistent with previously published sequences, except for the TCRAV
sequence ofclone CF8. This new TCRAV segment (assigned AV7S4) shows strong homology with TCRAV7 family sequences both at the nucleotide
and predicted amino acid level. TCRJ genuine sequences are underlined and in normal print. TCRBDI and TCRBD2 germline sequences are italicized
and underlined. The asterisk indicates a public TCR chain that is the same or structurally similar to a corresponding chain from a different individual (see
Fig. 5). These ot/l3 chain sequences are available from EMBL/Genbank under accession numbers Z49957, Z49924 (CF3/4); Z49956, Z49923 (CF24/
36/42); Z49903, Z49922 (CF8); Z49955, Z49921 (CF6/34/40); and Z49954, Z49920 (CF9), respectively.
and CDR3 regions. Within these oligoclonal repertoires, we
have identified several additional public TCR for FLR-
GRAYGL/HLA B8, wherein distinct a/R rearrangements
are shared by CTL clones from a number of unrelated indi-
viduals. These data strongly suggest genetic bias in TCR gene
rearrangement. In some cases, the identical a or (3 chains of
these public TCR were generated by different rearrange-
ment events wherein codon usage varies only within N re-
gions, also suggesting peptide-driven TCR selection.
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Gene
Tolerance to HLA B*4402 Obstructs the Normally Immuno-
dominant Response to a Distinct Determinant within the Non-
amer Peptide. To investigate the relationship between these
TCR structural differences and ligand recognition, the fine
specificity ofclones representing six different TCR sequences
was determined using a set of 171 monosubstituted peptide
analogues in which each residue within FLRGRAYGL was
sequentially replaced with all other genetically coded amino
acids. Peptides in which an amino acid had been deleted al-
CTL TCR V FN
Clone Gene
CF3 AV2S1 C A V
CF4 tgt gcc,gtg
CF24 AVIS1 C A V
CF36 tgt gee gtg
CF42
CF8' AV7S4 C A V
tgt get gtg
CF6' DV104S2'a C A M
CF34' tgt gca atg
CF40'
CF9 DV104S2'b C A M
tgt gca atg
LC13' AV4S1 C I L
tgc atc ctgCTL
￿
TCR V
￿
FW
￿
CDR3
￿
FW
￿
TCR J
Clone Gene
￿
Gene
RL10' AV7$4
￿
C A V R D Q T G A N N L
￿
F F G AJ17S5
RL45"
￿
tgt get gtg
￿
aga gat caa act aaa aca 'ac aac ctc
￿
ttc ttt ggg
Q G G K L
￿
I F G AJ14S2
caa aaa aca aaa ctt
￿
ate ttc gga
R A G K L
￿
I F G AJ14S2
agg gcA aaa aaa ett
￿
ate ttc gga
L F G N E K L
￿
T F G AJ17S8
ctt ttt cca aat aaa aaa tta
￿
ace ttt ggg
S L A A G S S N T G K L
￿
I F G AJ14S1
age etc gcc gcg ggc tet aac aac aca aac aaa eta
￿
ate ttt ggg
S S A G G F K T
￿
I F G AJIS4
agt tcg get aaa aac tte aaa act
￿
ate ttt gga
L F G N E K L
cta ttt aaa aat can aaa tta
D N S W G K L
￿
Q F G AJ1S9
gac aac aac taa aaa aaa tta
￿
cag ttt gga
L F G N E K L
￿
T F G AJ17S8
cta ttt yca aat aaa aaa tta
￿
aca ttt ggg
K S H T G N Q F
￿
Y F G AJ17S3
aaa agt eac ace act aac caa tte
￿
tat ttt ggg
L L H P E R Q D D N Y G Q N F V F G AJ13S2
cta ctg cat cct gag aga caa gac aac aac tat eat caa aat ttt
￿
gtc ttt ggt
B
CDR3
￿
FN
￿
TCR J TCR C
Gene Gene
S H G T S G I L E T Q
￿
Y F G BJ2S5 BC2
age cat aaa ac[ aac aaa ata ttg caa aca caa
￿
tac tte ggg
G Q G N F D I Q
￿
Y F G BJ2S4 BC2
ggt cao oot aac ttc gac att caa
￿
tac ttc ggc
T F G AJ17S8
ace ttt ggg
S Q G L S I S S Y E Q
￿
Y F G BJ2S7 BC2
age caa gcr7 ttg tcg ate age tea tag aaa caa
￿
tac tte ggg
S T N S L G E R E Y Y E Q Y F G BJ2S7 BC2
age aca aat tct etc ggg gaa coa aao tae tac man caa
￿
tae tte ggg
S Q G L A I S S Y E Q
￿
Y F G BJ2S7 BC2
age cao aoa cta aca ata ag r_ ten tac aaa c
￿
tac tte ggg
S L T T T G S N T G E L
￿
F F G BJ2S2 BC2
age tta acg aca aca aaa tca a c ace aaa aaa cta
￿
ttt ttt gga
S Q G L A I S S Y E Q
￿
Y F G BJ2S7 BC2
age caa ggt e_a aca att ag e tee tac can c
￿
tac tte ggg
S F S W T S G G A T D T Q Y F G BJ2S3 BC2
age ttt tct taa act aac aaa ggg gcg aca aat aca caa
￿
tat ttt ggc
S F S W T S G G A T D T Q Y F G BJ2S3 BC2
age ttt tct tgo act aac aaa ggg gcg aca aat aca caa
￿
tat ttt ggc
Figure 5.
￿
V-(D)Jjunctional region sequences ofu and(3 chains from CTLclones that recognize FLRGRAYGL/HLA 138 from the B*4402+ individ-
uals RL, IT, MH, and PP. TCRA (A) and TCRB (B) junctional region sequences of 10 CTL clones that recognize FLRGRAYGL/HLA 138, isolated
from four HLAB8+, B*4402+ donors, are presented. Clones RL10, RL45, RL42, and RL16 are from the donor RL; clones TF9 and TF1 are from the
donor TF; clone MH12 is from the donor MH; andclones PP7, PP22, andPP31 are from the donor PP. TCRV, J, and BC gene segments and CDR3
region loops are presented and assigned as outlined in the legend of Fig. 4. These a/(3 chain sequences are available from EMBL/Genbank under acces-
sion numbers Z49945, Z49953, Z49947 (RL10/45); Z49958, Z49864 (RL42); Z49952, Z49951, Z49930 (RL16); Z49959, Z49929 (TF9); Z49950,
Z49928 (TF1) ; Z49949, Z49927 (MH12); Z49948, Z49926 (PP7); Z49964, Z49925 (PP22); andZ49946, Z49925 (PP31), respectively.
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CTL TCR V FW
Clone Gene
RL10 " BV7S5 C A S
RL45 " tge gcc age
RL42 BV12S4 C A S
tgt gcc age
RL16 " BV7S1B C A S
tge gcc age
TF9 BV21S4 C A S
tgt gcc age
TF1" BV7S1B C A S
tge gcc age
MH12w BV21S4 C A S
tgt gcc age
PP7" BV7S1B C A S
tge gcc age
PP22` BV21S4 C A S
tgt gcc age
PP31" BV21S4 C A S
tgt gee age
AV6S1 C A S
tgt gcg tcc
RL42 AV2S8 C V V
tgt gtg gtt
RL16 " AV27S1 C A V
tgt gcc gtc
AV1S4 C A V
tgt get gtg
TF9 AV1S10 C V V
tgt gtt gtg
TF1' AV27S1 C A V
tgt gcc gtc
MH12 AV3S1 C A T
tgt get acg
PP7' AV27S1 C A V
tgt gcc gtg
PP22 " AV2S7 C T M
tgt acg atg
PP31 AV4S1 C C V
tgc tgt gtaae
J
U
U
N
IZ
N
60
40
0
60
40
10
0
60
40
20
0
60
40
20
0
60
40
0
60
40
:
o
Clones LC13 & CF24
￿
Clones CF3 & CF34
C E G I L N Q S V Y
D P ft R M P A T W
60
40
20
C E G I L N Q S V Y
￿
C E G 1 L N Q S V Y
A D F H K M P R T W "
￿
A D F H R M P R T W
1
Min I, Mi
￿
I
C 8 G I L N Q S V Y
A D P H K M P R T W
C E G I L N Q S V Y
￿
C E G I L N Q S V Y
A D F H K M P A T W "
￿
A D P H K M P R 7 W '
C E G I L N Q S V Y
A D F H K M P R T W "
￿
A D F H K M P K T W
60
40
20
60
40
xo
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￿
C E G 1 L N Q S V Y
A D F H K M P R T W "
￿
A D F H K M P A T W
C E G I L N Q S V Y
￿
C E G 1 L N Q S V Y
A D P H K M P R 7 W "
￿
A D F H K M P R T W
C E G I L N Q S V Y
￿
C E G 1 L N Q S V Y
A D F H K M P R T W '
￿
A D F H K M P R T W '
Replacement Amino Acid
together were also included (represented by asterisks). Each
peptide was tested for its capacity to sensitize HLA B8+
PHA blasts to lysis by the clones (Fig. 6). Only one con-
centration ofpepfde (100 nM) was used because ofthe num-
ber of peptides and clones tested. It should be noted that
dose-response curves for peptide FLRGRAYGL vary little
between clones expressing the different TCR (50G/G maxi-
mal activity observed at peptide levels between 7 and 16
nM), and all clones recognize endogenous antigen presented
on LCLs (data not shown).
The minimal antigenic determinant for all TCR is the
nonamer peptide FLRGRAYGL since truncation at the
NH2- or COOH-terminal ends results in loss of recogni-
60
40
28
0
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40
so
40
Clones PP22 & Mi12
'F
c E G I L N Q S V Y
A D F H K M P R 2 W
C E G I L N Q S V Y
A D P H K M P R T W
C E G i L N Q S V Y
A D F H K M P R T W
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P1
P2
P3
P4
P5
P6
P7
P8
P9
Figure 6. Recognition by CTL
clones using different TCR of
monosubstituted analogues o£ the
peptide FLRGRAYGL. Fine speci-
ficity analysis of CTL clones using
six different TCR (LC13, CF3, and
PP22, solid bars; CF24, CF34, and
MH12, open bars). Every one of the
20 genetically coded amino acids, as
well as a deletion (*), were tested in
each of the nine locations within the
parent sequence FLRGRAYGL.
The letter within each graph repre-
sents the parent residue being re-
placed; the horizontal axis lists the
residue replacing the parent residue.
P1-P9 at the right of the figure de-
note the position of the amino acid
substitution relative to the parent
peptide. Target cells were SC PHA
blasts, the peptide concentration was
100 nM, and the E/T was 1:1.
tion. The side chain of Phe at position 1 (P1), however,
does not appear to associate specifically with either HLA
B8 or the TCR that cross-reacts with HLA B*4402 (used
by CTL clone LC13), since all but two amino acids (Gly
and Pro) can be tolerated at this position without signifi-
cant detrimental effects on recognition by this TCR. This
implies that occupancy of P1 is a requirement for optimal
hydrogen bonding between the NHZ terminus of the pep-
tide main chain and HLA B8 (38). The intolerance of Pro
at P1 is probably caused by the disruption ofthis hydrogen
bond network because of the nature ofits side chain, which
is covalently attached to the peptide NHZ terminus (39) . The
overall proportion ofsubstitutions that leads to loss of anti-genic activity (defined as lysis levels below 10%) was shown
to vary only slightly between the different clones, ranging
from 56.7% for PP22 to 67 .8% for CF24.
TCR sequence variation between the clones is reflected
in unique fine specificity patterns. The previously defined
peptide binding motif for HLA B8 (x-x-K/R-x-K/R-x-x-
(x)-L/I) proposes that amino acid at P3, P5, and P9 are im-
portant MHC anchor residues (40). In good agreement with
this motif, analogues of the EBV peptide with Lys at P3 or
P5 are almost as active as the parent peptide. The effect of
other substitutions at these positions differs slightly between
the clones, suggesting that some may induce conforma-
tional changes in the peptide which indirectly affect the in-
teraction with some TCR (41). The high replaceability of
Leu at P9 appears to conflict with the HLA B8-specific mo-
tif. Since this is based on sequence homology between de-
fined HLA B8 restrictedviral epitopes rather than synthetic
peptide binding, however, our data support the view that
COOH-terminal amino acid selection ofendogenously pro-
cessed peptides is influenced by mechanisms upstream of class
I binding, such as antigen proteolysis or peptide transport (42) .
Certain destabilizing amino acid substitutions at positions
other than the primary anchor residues may also inhibit MHC
binding (43) .
Recent studies using x-ray crystallography of peptide pre-
sentation by several MHC class I alleles have shown that
four or five peptide side chains are directed out from the
binding cleft of the MHC and are therefore accessible to
TCR (39, 44-49). Since the side chains of amino acids at
P3, P5, and P9 of FLRGRAYGL have major roles in an-
choring the peptide to HLA B8, these are unlikely to be
potential TCR contact residues. In addition, Fig. 6 illus-
trates that Leu at P2 does not appear to associate specifically
with any of the TCR, a result that is consistent with the
known conformations ofpeptides bound to other MHC al-
leles in which P2 is buried deep in the cleft. Thus, residues
at P1, P4, P6, P7, and P8 of the peptide are the most likely
to be accessible to TCR.
As has been observed in larger class II-associated deter-
minants (50), a hierarchy in the importance of individual
residues in contacting the TCR is evident. Whereas several
are important for all T cell responses (P4, P6, and P7, where
the majority of replacements impaired recognition by all
clones), the fine specificity for secondary TCR contact res-
idues is unique for each receptor. Ofthe six different TCR
examined, none associate closely with the full set of poten-
tial TCR contact residues of the peptide. The most variation
between the different TCR in fine specificity pattern is at
P1 and P8, where either the side chain of Phe or the main
chain of Gly (which lacks a side chain) is more important
for recogntion by each clone. Whereas clones CF24, CF3,
CF34, PP22, and MH12 bind Phe at P1 more stringently,
LC13 interacts with amino acids toward the COOH termi-
nus of the peptide, including Gly at P8 . There are very few
significant differences between CF34 and PP22 in their rec-
ognition of peptide analogues. This is not surprising since
they express almost identical R chains and similar a chains.
Both can tolerate any substitution at P8, but only PP22 can
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accommodate the polar Tyr residue at P1, suggesting that
the TCR a chains of these clones lie over the NHZ termi-
nus ofbound peptide. A similar orientation has been pro-
posed for TCR that are specific for other peptides (3, 51).
The fine specificities of several other clones using identi-
cal TCR to LC13, CF24, CF3, and CF34 were also deter-
mined and found to be analogous with data presented in Fig.
6 (datanot shown) . CTL clone CF8, expressing a seventh dis-
tinct TCR, was also screened for recognition ofthe peptide
analogues. In contrast to other clones tested from HLA
B*4402+ individuals, this clone displays a similar fine spec-
ificity pattern to clone LC13 with just two major excep-
tions (data not shown). At P8, the requirement for the na-
tive residue (Gly) is absolute for clone CF8, while clone LC13
can tolerate two conservative substitutions (Ala and Set) .
Discussion
By exploiting the unusual characteristics of the memory
CTL response to an antigenic determinant ofEBV, we have
demonstrated, for the first time in humans, how the TCR
repertoire for a foreign epitope is influenced markedly by an
MHC allele that is not involved in presenting the epitope.
Self tolerance to a conventional antigen, in the form o£ a
background MHC protein, leads to the diversification of a
memory response that is commonly dominated by a single
public TCR.
TCR Repertoire Diversity.
￿
Many factors may contribute
to variation in the size of antigen-selected TCR repertoires.
These include antigen-dependent and -independent events.
One proposal is that the degree of diversity in TCR usage
may be critically dependent on structural constraints imposed
by particularpeptide/MHC combinations, and that the avail-
able receptors that can make a "close-fit" interaction is depen-
dent on the target structure (52) . Another proposal suggests
that the diversity of T cell responses is often restrictedby tol-
erance to self-proteins that are homologous, but not identi-
cal, to foreign antigens (53) . In this model, antigenic pep-
tides that are similar to self-determinants and bound to the
same restriction element will stimulate a limited response.
When considered in the context ofdata presented herein, the
highly restricted TCR repertoire used for the memory re-
sponse to peptide FLRGRAYGL in the absence of HLA
B*4402 (20) cannot be explained simply by either of these
proposals . Rather, it is likely to reflect selective T cell mat-
uration and expansion in the periphery as a result ofchronic
immune stimulation. According to the balance of growth
model (54), a T cell clone that best responds to a foreign pep-
tide could, with time, dominate over other clones that have
also been stimulated during the primary response. EBV is a
gamma herpes virus that is thought to persist as a latent in-
fection in B cells. Thus, marginal antigen concentrations on
infected B cells after convalescence could stimulate prefer-
entially a CTL clone with the highest proliferative capacity.
Consistent with this model, we have demonstrated that,
when T cells using a dominant TCR are inactivated by
mechanisms ofself-tolerance, a new TCR hierachy is estab-
lished such that CTL expressing alternative TCR becomeapparent. This hierachy is most likely a result ofquantitative
differences in signaling through the TCR upon binding to
the peptide/MHC complex. Recent reports have suggested
that TCR signaling is influenced, not only by the affinity/
avidity of the TCR-ligand interaction, but also by confor-
mational changes in the TCR (55).
The data presented herein suggest that the memory re-
sponse to peptide FLRGRAYGL can be influenced, not only
by self-tolerance and peripheral T cell selection, but also by
bias at the TCR gene recombination level. Individuals ex-
pressing both HLA B8 and B*4402 mount an oligoclonal
T cell response to the EBV peptide. Comparison of TCR
sequences from five such individuals revealed an unex-
pected number ofpublic or shared TCR. Indeed, >60% of
clones from the unrelated donors express public receptors
with highly homologous (3 or a/p rearrangements; a sur-
prising observation given the enormous potential diversity
of the TCR repertoire. Theoretically, if it is assumed that
the processes of V, D, and J combinatorial joining, exonu-
cleolytic nibbling, and N nucleotide insertions operate ran-
domly, then the potential number ofavailable a/(3 specific-
ities range from 1015 to 102° (2, 56). Despite this potential
and the fact that the number oflymphocytes present at any
time in the adult human is -1012, we have described the
recurrence of identical TCR-a and/or -R chains in unre-
lated individuals. Moreover, this public TCR response pre-
dominates in the (3 chain ofthe heterodimer, which has the
greater potential for diversity (-5 X 1012), since it contains
two D regions and it has the added potential of N additions
at both the V-D and D-J junctions (56). Notably, several of
these identical a and/or (3 rearrangements were generated
by complex recombination events involving exonucleolytic
trimming and addition of nongermline-encoded N nucle-
otides. Taken together, these observations provide evi-
dence for strong genetic bias in TCR recombination. In-
deed, several studies have suggested nonrandomness in the
TCR recombination process (57, 58) .
Recently, a public TCR VP rearrangement has been re-
ported in the human T cell response to the influenza pep-
tide, M58-66 (59). In this study, BV17+ T cells were shown
to dominate in 13 individuals, and identical TCR-R protein
chains were identified in clones from five individuals. A pub-
lic V(3 TCR has also been documented in the murine re-
sponse to hen egg lysozyme, where a single V(3 rearrange-
ment dominates the TCR repertoire (21) . This dominant
public V(3 rearrangement is exclusively germine encoded. By
comparing these mice with transgenic mice low in hen egg
lysozyme, the authors further showed a private TCR com-
ponent for the same epitope that was specific to each mouse.
These private TCR were unlike the dominant public TCR
in that they involved nongermline-encoded N additions in
their VP rearrangements. The distinction between these pre-
vious studies and the present report is that we have identified
both a and (3 chain conservation for multiple TCR directed
against a single antigenic determinant. The unprecedented
level of TCR conservation we have documented suggests
that the occurrence ofT cells expressing public receptors may
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be frequent in memory responses to certain peptides, espe-
cially in immunological environments where antigen per-
sists. Furthermore, our study shows that the public arm of
an immune response can consist of multiple TCR that dis-
play diverse CDR3, V, and J gene usage in both the a and
(3 chains.
The present report contests the conclusions of a previous
analysis of the murine T cell response to a 12-mer peptide
of sperm whale myoglobin that binds MHC class II (15) .
Their study demonstrated a strict association between rec-
ognition of distinct determinants within the peptide and
TCRBV usage, concluding that T cell responses that appear
diverse may be restricted when viewed from the perspec-
tive ofindividual determinants. Although we agree that TCR
diversity is, in part, a reflection ofthe recognition of distinct
determinants within a bound peptide, our TCR structure/
function analysis (Figs. 4-6) also revealed that the same de-
tenninant of exposed residues within peptide FLRGRAYGL
can be recognized by receptors with no apparent common
structural motifs within their CDR3 regions. The diversity
of CDR3, V, and J gene usage in both the a and (3 chains
of TCR for the EBV peptide FLRGRAYGL provides an
excellent example of the remarkable plasticity of the TCR
repertoire.
TCR Cross-reactivity.
￿
Our data (Fig. 6), together with
previous reports (51, 60), demonstrate that simple class I-asso-
ciated nonamer peptides may generate multiple determinants
when associated with a single MHC molecule, as has been
demonstrated for longer peptides that bind class II (15, 41,
50, 61) . A feature of many T cell clones used in these stud-
ies and in our investigation is that their TCR interact strin-
gently with either anuno acids toward the COOH- or the
NH2-terminus of the peptide. A core region is important for
all T cell responses, whereas secondary TCR contact residues
often vary between distinct receptors. Thus, a peptide's full
array ofpotential TCR contact residues is rarely used by in-
dividual clones. It is unlikely that this curious feature is
caused by the inability of a and R chain CDR3 loops to
span the 2.5-nm groove length ofclass I MHC since model-
ing of TCR structure, based on immunoglobulin folds, sug-
gests they can (37). Alternatively, T cells that fail to engage
amino acids at both ends of a peptide are perhaps more
likely to be both positively selected in the thymus and re-
sponsive to a nonselfantigen, given recent evidence that pos-
itive selection is dependent on particular endogenous pep-
tide/MHC complexes (6, 7) .
It can be calculated, based on the number ofamino acids
encoded in a higher vertebrate genome (^"3 X 107 to 101),
that peptides not less than eight to nine residues in length
are required for adequate self versus nonself discrimination
(62) . Since many T cells fail to "view" the full-length of
bound peptides, it is not surprising that individual TCR bear-
ing dual specificities are a common occurrence (63) . These
may have an important role in the overall functioning of
the immune system. For example, the impact of a point mu-
tation within a foreign peptide epitope will be reduced if
the TCR repertoire includes receptors that do not interactwith the altered peptide position. In addition, broadly reac-
tive T cells may aid primary (64) and memory responses (65),
where memory T cells for one pathogen are reactivated by
a different infectious agent.
The limited specificity of self-MHC-restricted T cells is
also the basis of the alloresponse and its associated clinical
problems. This is supported by numerous reports of T cell
clones with dual specificity for an allo-MHC molecule and
a nominal antigen complexed with self-MHC (63) . The T
cell clonotype expressing the prototypical TCR for peptide
FLRGRAYGL is an example, and we have shown that the
potent memory response to this peptide that persists after
primary EBV exposure augments the alloresponse to HLA
B*4402 (22). It is now clear that, in most cases, T cell rec-
ognition of alloantigens involves both the allo-MHC mole-
cule and its associated peptide ligand (66). It seems possible,
based on the fine specificity analysis (Fig. 6), that the dual
reactivity of the prototypical receptor for FLRGRAYGL
(see clone LC13) is related to its failure to bind specifically
to the NHZ-terminal amino acid of the peptide. Perhaps a
determinant toward the COON terminus ofthe EBV pep-
tide resembles a peptide presented on HLA B*4402. Sup-
porting this concept, most of the clones we have examined
from B*4402+ donors interact relatively stringently with
Phe at P1 . An exception, however, is clone CF8, which rec-
ognizes the same residues of FLRGRAYGL as the cross-
reactive clone, although slightly more specifically. The TCR
of clone CF8 may avoid self-reactivity by binding MHC
residues that differ between HLA B8 and B*4402. Alterna-
tively, differences in the stringency ofinteraction with MHC
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